# Tigatuzumab

**Cat. No.:** HY-P99270

**CAS No.:** 918127-53-4

**Target:** Apoptosis

**Pathway:** Apoptosis

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## BIOLOGICAL ACTIVITY

**Description**

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].

**In Vitro**

Tigatuzumab is sensitive to MIA PaCa-2 cells and BxPC-3 cells with $IC_{50}$ values of 2.95 and 8.21 μg/mL, respectively[1].
Tigatuzumab (3-8 μg/mL; 5 h) induces apoptosis of cancer cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

| | |
|---|---|
| Cell Line: | MIA PaCa-2 and BxPC-3 cell lines |
| Concentration: | 3 and 8 μg/mL |
| Incubation Time: | 5 hours |
| Result: | Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells. |

**In Vivo**

Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|---|---|
| Animal Model: | Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection[1] |
| Dosage: | 3 mg/kg |
| Administration: | Intravenous injection; 3 mg/kg weekly for 4 weeks |
| Result: | Reduced the tumor volume and decreased the density of viable cancer cells in tumors. |

## REFERENCES

[1]. Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an

orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA